Investigational Drug Details
| Drug ID: | D240 |
| Drug Name: | Dobutamine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00841 |
| DrugBank Description: | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. |
| PubChem ID: | 36811 |
| CasNo: | 34368-04-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1 |
| Structure: |
|
| InChiKey: | JRWZLRBJNMZMFE-UHFFFAOYSA-N |
| Molecular Weight: | 301.3801 |
| DrugBank Targets: | Alpha-1 adrenergic receptors; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Estrogen receptor alpha |
| DrugBank MoA: | Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. |
| DrugBank Pharmacology: | Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. |
| DrugBank Indication: | Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1718 | NCT00077597 | PHASE3 | COMPLETED | NO | 2004-02 | 2016-11-02 | Details |
| L6610 | NCT02771093 | PHASE4 | COMPLETED | YES | 2016-09-08 | 2023-12-12 | Details |
| L6992 | NCT02416193 | PHASE2 | TERMINATED | YES | 2015-09-23 | 2020-10-23 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|